DolPHIN2

RT @hivinteractions: New comedications added to the HIV site Dronedarone (Antiarrhythmics) Apalutamide (Cancer therapies) Bempedoic acid, Icosapent ethyl, Omega-3 fatty acids (Lipid Lowering Agents) Omega-3 fatty acids [in multivitamins] (Herbals/Supplements/Vitamins) Tirzepatide (Anti-diabetics)

DolPHIN2 investigator @CatrionaWaitt paper was mentioned at #ChivaConference during the #breastfeeding session. Check out the paper here https://t.co/o0H1kwQiDQ

RT @UNITAID: On #InternationalWomensDay, 8 March, Unitaid remains committed to addressing barriers to improve the lives and health of women in resource-constrained settings. Discover how Unitaid is bridging the gender divide through access to life-saving innovations: https://t.co/o2mhyMNqbo https://t.co/HiqKLimxNK

Laura Else from @LivUniISMIB will be presenting a poster at #CROI2023 today at 14 30 entitled Plasma & urine PK of #dolutegravir and #tenofovir to aid point-of-care testing. Stop by poster 527 to find out more

RT @covidDDIs: #CROI2023 Stop by poster 515 TODAY at 2h30 pm for a live discussion to learn more about the global collaboration to provide drug interaction guidance for nirmatrelvir/ritonavir @AlicePharmd @FionaMarra @alisonboyle_1 @geschena @KimScarsi

RT @AdellineTwimu: We successfully disseminated research findings to study participants. Thank you #DolPHIN2 team for making this happen! https://t.co/7FJrsOUl5M

RT @CatrionaWaitt: The @UoLDolphin2 participant feedback event reminded us all of the power of research to transform lives. Many emotional testimonials from participants of how involvement in the trial brought hope and healing. @UNITAID @TRIO_ARToptim @livuniHLS @IDIMakerere @radboudumc @UCT_news https://t.co/gX4zhmPdVT

RT @UNITAID: The @UoLDolphin2 programme investigates the safety and efficacy of dolutegravir in pregnant HIV+ women and their neonates. Find out more about the final 72-week postpartum results in @TheLancet: https://t.co/O9WmgzpDTu https://t.co/p59Zv3dlWC

We are recruiting a NIHR Academic Clinical Lecturer in Clinical Pharmacology and Therapeutics at University of Liverpool https://t.co/gRrI5C7LQ0

On #WorldAIDSDay we would like to thank all the participants for their time and commitment to the DolPHIN2 trial

RT @AdellineTwimu: Please follow the link below to join the forum through zoom; Dolutegravir in Pregnant HIV Mothers and their Noenates- (DoLPHIn 2) https://t.co/BW8V7GzVIn @IDIMakerere @UoLDolphin2 https://t.co/VNQIRcH5GS

RT @UNITAID: In sub-Saharan Africa, over 1 in 5 HIV-infected pregnant women are diagnosed in late pregnancy each year. @UoLDolphin2 investigates factors that influence late antenatal initiation and the adherence to and retention in combination antiretroviral therapy programmes in pregnancy. https://t.co/gds9CbxJGZ